Hepatitis B Country Profile

Country Demographics\(^1, 2, 6\)

<table>
<thead>
<tr>
<th>Total Population (2020)(^6)</th>
<th>19,398,448</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban Population (% of total, 2020)(^6)</td>
<td>55.5%</td>
</tr>
<tr>
<td>Health expenditure per capita ($US, 2012)(^1)</td>
<td>69.89</td>
</tr>
<tr>
<td>Health expenditure, total (% of GDP, 2012)(^1)</td>
<td>3.57</td>
</tr>
<tr>
<td>Total births (2013)(^2)</td>
<td>532,000</td>
</tr>
<tr>
<td>Surviving Infants (2013)(^2)</td>
<td>522,000</td>
</tr>
<tr>
<td>Life expectancy at birth (years, 2020)(^6)</td>
<td>73.7 years</td>
</tr>
<tr>
<td>Number of districts (2013)(^2)</td>
<td>75</td>
</tr>
</tbody>
</table>

HBsAg Prevalence\(^3\)

| Pre-vaccine HBsAG+ (%) | 1.8% |

Liver Cancer as Cause of Cancer Death (in Men)\(^4\)

| Year: 2018 | Ranking: 11 |

2019 Country Comparison in Eastern Mediterranean Region (21 Countries)\(^5\)

<table>
<thead>
<tr>
<th>Syrian Arab Republic</th>
<th>Number of countries with reported coverage</th>
<th>Highest reported coverage in EMR</th>
<th>Lowest reported coverage in EMR</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3(^5)</td>
<td>54%</td>
<td>21</td>
<td>99% (Bahrain, Iran, Morocco, Oman)</td>
</tr>
<tr>
<td>HepB BD(^5)</td>
<td>NR</td>
<td>14</td>
<td>99% (Oman)</td>
</tr>
</tbody>
</table>

Hepatitis B Immunization Coverage\(^5\)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3(^5)</td>
<td>79%</td>
<td>80%</td>
<td>80%</td>
<td>81%</td>
<td>82%</td>
<td>83%</td>
<td>83%</td>
<td>83%</td>
<td>84%</td>
<td>84%</td>
<td>66%</td>
<td>43%</td>
<td>71%</td>
<td>47%</td>
<td>41%</td>
<td>42%</td>
<td>48%</td>
<td>47%</td>
<td>54%</td>
</tr>
<tr>
<td>HepB BD(^5)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>DTP3(^5)</td>
<td>84%</td>
<td>82%</td>
<td>84%</td>
<td>83%</td>
<td>81%</td>
<td>80%</td>
<td>80%</td>
<td>80%</td>
<td>79%</td>
<td>80%</td>
<td>72%</td>
<td>45%</td>
<td>41%</td>
<td>43%</td>
<td>41%</td>
<td>42%</td>
<td>48%</td>
<td>47%</td>
<td>54%</td>
</tr>
<tr>
<td>BCG(^5)</td>
<td>91%</td>
<td>91%</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
<td>91%</td>
<td>93%</td>
<td>93%</td>
<td>95%</td>
<td>97%</td>
<td>90%</td>
<td>82%</td>
<td>84%</td>
<td>81%</td>
<td>66%</td>
<td>72%</td>
<td>78%</td>
<td>79%</td>
</tr>
</tbody>
</table>

Syrian Arab Republic: HepB3 vs. DTP3

Syrian Arab Republic: BCG

Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database\(^1\), WHO Immunization Summary: A statistical reference containing data through 2013\(^2\), WHO Public Health Significance, Targets, Strategies: HBV country profiles\(^3\), Global Cancer Observatory: Cancer Today-IARC\(^4\), WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates\(^5\), CIA The World Factbook\(^6\).